Skip to main content
OpenTrials
Completed

NCT Number: NCT01561794

A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia

The main objective of this study is to investigate the safety, pharmacokinetics (PK) and the relationship between PK and pharmacodynamics (Minimum Inhibitory Concentration [MIC] and Mutant Prevention Concentration [MPC]) of intravenous BAYQ3939 (400 mg BID and 400 mg TID) in hospitalized patients with bacterial pneumonia or secondary infection of chronic respiratory disease with severe disease or a poor response to other antimicrobials. In addition, the efficacy of the ciprofloxacin, in terms of clinical response and microbiological response, will be investigated, but as a secondary endpoint.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pneumonia Bacterial Infections Bacterial Infections and Mycoses Community-Acquired Infections Community-Acquired Pneumonia Cross Infection Disease Attributes Healthcare-Associated Pneumonia Iatrogenic Disease Infections Lung Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia, Bacterial Respiratory Tract Diseases Respiratory Tract Infections

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Nagakute, Aichi-ken, Japan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and non-pregnant, non-lactating females with written informed consent, 20 years of age or older.
  • Within 48 hours prior to the first study drug administration, all patients should have the pathogens identified with appropriate specimens (e.g., sputum, tracheal aspirate, bronchoalveolar lavage [BAL], protected brushing specimen [PBS]), or should have appropriate specimens highly likely to identify the pathogens sampled. (However, the patients with Legionellosis is enrolled when the test of Legionella antigen is positive.)
  • The following severe bacterial pneumonia meeting the diagnostic criteria of pneumonia or secondary infection of chronic respiratory disease
  • Severe pneumonia
  • Community-acquired pneumonia: PORT score III, IV or V
  • Hospital-acquired pneumonia [HAP]-Group B and with a low risk for multidrug-resistant pathogens
  • Patients with [HAP]-Group A whose pathogen is suspected to be Pseudomonas aeruginosa
  • Hospitalized patients with bacterial pneumonia with a poor response to other antimicrobials Note: The patients should be limited to CAP patients with PORT score III, IV or V and HAP patients with-Group A or B who don't respond to or have a poor response to other antimicrobials over 3day's treatment.2
  • Secondary infection of chronic respiratory disease
  • Patients who are hospitalized for the treatment of secondary infection of chronic respiratory disease
  • Hospitalized patients with secondary infection of chronic respiratory disease with a poor response to other antimicrobials Note: The patients should be limited to secondary infection of chronic respiratory disease patients who don't respond to or have a poor response to other antimicrobials over 3day's treatment.

Exclusion criteria

  • Creatinine clearance (Ccr) ≤ 30 mL/min or nephrotic syndrome
  • Patient with chronic treatment of immunosuppressive drug
  • Decompensated congestive heart failure
  • Subject who received more than 24 hours of an antibacterial drug for the current infection
  • Patient who requires Intensive Care Unit (ICU) management [In case subjects who don't correspond to the severity for ICU management need to be admitted to ICU due to a circumstance of the site (e.g. shortage of hospital beds), those subjects shall not be excluded]
  • Patients with infections other than pneumonia or secondary infection of chronic pulmonary disease
  • Lung abscess, or empyema
  • Viral, fungal, mycobacterial, or atypical pneumonia as a primary diagnosis
  • Known or suspected bacteremia secondary to Staphylococcus aureus
  • Known causative microorganisms other than indication (microorganisms) of the study drug, or positive in urinary antigen test of Streptococcus pneumonia
  • Infection that necessitates the use of a concomitant antibacterial agent in addition to study medication [excluding subjects with concomitant use of long-term, low-dose macrolide for chronic respiratory diseases, sulbactam sodium/ampicillin sodium (Unasyn-S) and clindamycin (Dalacin-S)]
  • Known bronchial obstruction or a history of post-obstructive pneumonia
  • Known primary lung cancer

Treatment and study plan

Ciprofloxacin (Cipro, BAYQ3939)

Drug

(1) Community-acquired pneumonia (CAP): 400 mg BID, i.e. every 12 ± 1 hours (For those with Ccr > 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days.

  • Hospital-acquired pneumonia (HAP): For the patient with Ccr > 60 mL/min, 400 mg TID, i.e. every 8 ± 1hours for 7 to 14 days For the patient with 30 ≤Ccr ≤60 mL/min, 400 mg BID, i.e. every 12 ± 1hours for 7 to 14 days 3) Secondary infection of chronic respiratory disease 400 mg BID, i.e. every 12 ± 1 hours (For those with of Ccr > 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days.

Primary outcomes

  1. Safety variables will be summarized using descriptive statistics based on adverse events collection

    Time frame: Up to 30 (±5) days after the end of treatment

  2. AUC (Area under the blood concentration/time curve)

    Time frame: Within 0-24 hours and 48-72 hours after the first study drug administration

  3. Cmax (Maximum observed concentration)

    Time frame: Within 0-24 hours and 48-72 hours after the first study drug administration

  4. AUC/MIC (Minimum inhibitory concentration)

    Time frame: Within 0-24 hours and 48-72 hours after the first study drug administration

  5. Cmax/MIC

    Time frame: Within 0-24 hours and 48-72 hours after the first study drug administration

  6. AUC/MPC (Mutant prevention concentration)

    Time frame: Within 0-24 hours and 48-72 hours after the first study drug administration

  7. Cmax/MPC

    Time frame: Within 0-24 hours and 48-72 hours after the first study drug administration

Secondary outcomes

  1. Clinical response rate based on resolution of signs and symptoms

    Time frame: Up to 13 days after the first study drug administration

  2. Microbiological response rate, assessed as eradication rate based on microbiologically evaluable patients

    Time frame: Up to 23 days after the first study drug administration

  3. Test of cure rate based on resolution of signs, symptoms, and the clinical response

    Time frame: Up to 23 days after the first study drug administration

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

A Prospective, Non-randomized, Open-label, Non-controlled, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics/ Pharmacodynamics of BAYQ3939 (400 mg BID and TID) in Hospitalized Patients With Bacterial Pneumonia or Secondary Infection of Chronic Respiratory Disease With Severe Disease or a Poor Response to Other Antimicrobials

Important dates

Study start
2012
Primary completion
2015
Study completion
2015
First posted
Mar 23, 2012
Registry last updated
Apr 27, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.